MA29145B1 - Préparations pharmaceutiques pour le traitement de la cellulite - Google Patents

Préparations pharmaceutiques pour le traitement de la cellulite

Info

Publication number
MA29145B1
MA29145B1 MA30067A MA30067A MA29145B1 MA 29145 B1 MA29145 B1 MA 29145B1 MA 30067 A MA30067 A MA 30067A MA 30067 A MA30067 A MA 30067A MA 29145 B1 MA29145 B1 MA 29145B1
Authority
MA
Morocco
Prior art keywords
cellulite
treatment
pharmaceutical preparations
preparations
mesotherapy
Prior art date
Application number
MA30067A
Other languages
English (en)
Inventor
Massimiliana Landini
Sandro Giuliani
Alessandro Giolitti
Original Assignee
Menarini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20042371 external-priority patent/ITMI20042371A1/it
Priority claimed from ITMI20051739 external-priority patent/ITMI20051739A1/it
Application filed by Menarini Ricerche Spa filed Critical Menarini Ricerche Spa
Publication of MA29145B1 publication Critical patent/MA29145B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRÉSENTE INVENTION DÉCRIT DES PRÉPARATIONS PHARMACEUTIQUES POUR ADMINISTRATION LOCALE OU POUR EMPLOI DANS LE CADRE D'UNE MÉSOTHÉRAPIE, AINSI QUE LEUR UTILISATION DANS LE TRAITEMENT DE LA CELLULITE. LESDITES PRÉPARATIONS CONTIENNENT UN INHIBITEUR DE PDE3 AU TITRE DE PRINCIPE ACTIF.
MA30067A 2004-12-14 2007-07-12 Préparations pharmaceutiques pour le traitement de la cellulite MA29145B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20042371 ITMI20042371A1 (it) 2004-12-14 2004-12-14 Composizioni farmaceutiche topiche per il trattamento della cellulite
ITMI20051739 ITMI20051739A1 (it) 2005-09-20 2005-09-20 Composizioni farmaceutiche topiche per il trattamento della cellulite

Publications (1)

Publication Number Publication Date
MA29145B1 true MA29145B1 (fr) 2008-01-02

Family

ID=35708888

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30067A MA29145B1 (fr) 2004-12-14 2007-07-12 Préparations pharmaceutiques pour le traitement de la cellulite

Country Status (17)

Country Link
US (1) US20100016324A1 (fr)
EP (1) EP1824463A1 (fr)
JP (1) JP2008523127A (fr)
KR (1) KR20070086101A (fr)
AR (1) AR052048A1 (fr)
AU (1) AU2005315919B2 (fr)
BR (1) BRPI0518554A2 (fr)
CA (1) CA2590288A1 (fr)
IL (1) IL183893A0 (fr)
MA (1) MA29145B1 (fr)
MX (1) MX2007007015A (fr)
NO (1) NO20073575L (fr)
NZ (1) NZ555836A (fr)
PE (1) PE20060746A1 (fr)
RU (1) RU2401098C2 (fr)
TN (1) TNSN07203A1 (fr)
WO (1) WO2006063714A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100963268B1 (ko) 2006-11-22 2010-06-11 에스케이케미칼주식회사 실로스타졸과 은행잎 추출물을 함유한 약제 조성물
ITMI20070604A1 (it) * 2007-03-26 2008-09-27 Menarini Farma Ind Preparazioni cosmetiche per la riduzione degli inestetismi della cellulite
JP6006940B2 (ja) * 2009-03-02 2016-10-12 ヘクセル,ドリス 医学的美容脂肪萎縮方法
MY170724A (en) 2012-01-27 2019-08-27 Biotropics Malaysia Berhad Use of certain trioxygenated benzene derivatives in body fat management
CN104161756B (zh) * 2014-06-13 2017-02-01 河北智同医药控股集团有限公司 一种盐酸奥普力农注射液组合物
EA031658B1 (ru) * 2017-06-30 2019-02-28 Акционерное Общество "Верофарм" Антицеллюлитный косметический комплекс
RU2694898C1 (ru) * 2018-08-29 2019-07-18 Талагаева Елена Владимировна Крем для лица и тела

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147497A (en) 1977-01-04 1979-04-03 Gte Sylvania Incorporated Hand-operable signal device using percussively-ignitable flashlamps
FR2714598B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition amincissante à deux types de liposomes pour traitement topique, son utilisation.
IT1270602B (it) 1994-07-12 1997-05-07 Indena Spa Formulazioni a base di esculoside e loro uso in campo farmaceutico e cosmetico
JP3452986B2 (ja) * 1994-09-13 2003-10-06 花王株式会社 脂肪分解促進剤
JP4182183B2 (ja) 1999-08-24 2008-11-19 ディーエスエム アイピー アセッツ ビー.ブイ. 痩身用皮膚化粧料
WO2001035979A2 (fr) * 1999-11-13 2001-05-25 Icos Corporation Therapie combinant des inhibiteurs de pde3 et de pde4 pour le traitement de l'obesite
FR2802811B1 (fr) * 1999-12-24 2002-02-15 Silab Sa Procede d'extraction d'un principe actif a partir de petales de bigarade, notamment pour le traitement de la cellulite, principe actif obtenu, compositions cosmetiques et traitements adaptes
AU2001238363A1 (en) * 2000-02-15 2001-08-27 Zen Bio, Inc. Compositions for preventing cellulite in mammalian skin
DE10009423A1 (de) 2000-02-28 2001-09-06 Henkel Kgaa Kosmetische und pharmazeutische Zubereitungen
DE10009424A1 (de) * 2000-02-28 2001-09-06 Henkel Kgaa Verwendung von Flavonen oder Isoflavonen zur Cellulite-Behandlung
AU2002247208A1 (en) * 2001-03-05 2002-09-19 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
ITMI20011182A1 (it) * 2001-06-05 2002-12-05 Indena Spa Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite
ITFI20010133A1 (it) * 2001-07-13 2003-01-13 El En Spa Apparecchiatura anti cellulite a tecniche composite
RU2183967C1 (ru) * 2001-08-08 2002-06-27 Закрытое акционерное общество "Коммерческий центр "НИЗАР" Способ лечения целлюлита
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat

Also Published As

Publication number Publication date
JP2008523127A (ja) 2008-07-03
IL183893A0 (en) 2007-10-31
WO2006063714A1 (fr) 2006-06-22
MX2007007015A (es) 2007-07-04
AU2005315919B2 (en) 2011-06-09
AR052048A1 (es) 2007-02-28
RU2007120465A (ru) 2009-01-27
KR20070086101A (ko) 2007-08-27
RU2401098C2 (ru) 2010-10-10
CA2590288A1 (fr) 2006-06-22
NO20073575L (no) 2007-09-13
US20100016324A1 (en) 2010-01-21
EP1824463A1 (fr) 2007-08-29
TNSN07203A1 (en) 2008-11-21
BRPI0518554A2 (pt) 2008-11-25
PE20060746A1 (es) 2006-09-06
HK1111599A1 (en) 2008-08-15
AU2005315919A1 (en) 2006-06-22
NZ555836A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
EP1604664A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA27311A1 (fr) Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
EP1429729A4 (fr) Forme dosifiee de melange renfermant un hypocholesterolemiant, un inhibiteur de la renine-angiotensine, et de l'aspirine
MA34002B1 (fr) Thérapie antivirale
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
EE200200500A (et) Uus iseemulgeeruv ravimi manustamise süsteem
FR2856294B1 (fr) Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
EP0934065A4 (fr) Composes pharmaceutiques
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
FR2930552B1 (fr) N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
EP1781277A4 (fr) Composition combinee
MA20150235A1 (fr) Utilisation de composition a base d'extraits de microalgues marines pour le traitement d'acne
EP1896005A4 (fr) Préparations pharmaceutiques synergiques pouvant être employées dans le traitement prophylactique et thérapeutique d'une maladie induite par la protéine bêta-amyloïde, incluant des composés dérivés de la sauge et du romarin